A T-Cell Tweak Combats Advanced Breast Cancer

The immunotherapy eliminated a woman’s metastatic lesions and kept her disease-free for two years.

Written byAshley Yeager
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ISTOCK, MELETIOS VERRASReactivating T cells in a woman with metastatic breast cancer eliminated her tumors, researchers report today (June 4) in Nature Medicine. It is the first time late-stage breast cancer has been successfully treated with T-cell immunotherapy.

“We’re looking for a treatment—an immunotherapy—that can be broadly used in patients with common cancers,” study coauthor Steven Rosenberg, an oncologist and immunologist at the National Cancer Institute (NCI), tells NPR. The result suggests this type of treatment might be possible for other types of solid tumors, including in the colon, rectum, and pancreas.

To develop the treatment, Rosenberg and his colleagues used whole-exome and RNA sequencing to identify point mutations within the genome of a patient’s breast tumor and then isolated tumor-infiltrating lymphocytes from the mass and identified which ones were reactive against mutations in the genes SLC3A2, ECPAS, CADPS2, and CTSB, which were present in her tumor. The researchers then infused into the patient roughly 90 billion tumor-infiltrating lymphocytes that targeted the four ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies